Fig. 6: Potent therapeutic efficacy of PrEXO-a23 against IBD.
From: Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease
a Experimental design for evaluating the therapeutic effect of PrEXO-a23 in the IBD mouse model. b, c Body weight change (b) and total DAI scores (c) during the experiment. On day 8, mice were euthanized. d Photographs of colon tissues and corresponding colon lengths. e Representative H&E-stained images of colon sections and histopathological damage scores. Scale bars, 100 μm. f Representative ZO-1 and Occludin labeling staining images of colon tissues and relative expression levels. Green: ZO-1; Red: Occludin; Blue: nucleus; Scale bars, 100 μm. g–i Gut microbiota analysis. Circos diagram of relative abundance for gut microbiome at family level (g), relative abundance of dominant bacterial families (h), and distribution histogram based on linear discriminant analysis (LDA) using the LEfSe method (i). LDA score (LDA (log10) >4.0, P < 0.05) cutoff was set at the top 5. For (b–f, h), data were presented as mean ± SD (n = 5 mice in b–d, h; n = 3 mice in e, f). For (d–f, h), statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test. Source data are provided as a Source Data file.
